Correct Answer: B. Protein degradation
The proteasome is a large, barrel-shaped, multi-subunit protease complex (26S proteasome) responsible for selective protein degradation in eukaryotic cells. Its primary function is to recognize and degrade proteins tagged with ubiquitin, a small regulatory protein. The ubiquitin-proteasome system (UPS) is the major pathway for intracellular protein degradation and plays a critical role in cell cycle regulation, signal transduction, apoptosis, and removal of misfolded proteins. Proteins destined for degradation are first conjugated to ubiquitin by ubiquitin-activating enzymes (E1), ubiquitin-conjugating enzymes (E2), and ubiquitin ligases (E3). The polyubiquitinated protein is then recognized by the 19S regulatory particle of the proteasome, unfolded, and threaded into the 20S catalytic core where proteolytic cleavage occurs. This system is essential for maintaining cellular protein homeostasis and is a major target for cancer therapeutics (e.g., bortezomib in multiple myeloma). Defects in proteasomal degradation are implicated in neurodegenerative diseases like Parkinson's disease and Alzheimer's disease, making this a high-yield concept for Indian medical examinations.
Why the other options are wrong
A. Protein folding — This is wrong because protein folding is the function of molecular chaperones (Hsp70, Hsp90, chaperonins), not the proteasome. While chaperones assist in proper protein folding and prevent aggregation, the proteasome actively degrades misfolded proteins that cannot be rescued. NBE may trap students who confuse the proteasome's role in quality control with the chaperone's role in folding assistance. C. Post-translation modification — This is wrong because post-translational modifications (phosphorylation, ubiquitination, glycosylation, acetylation) are catalyzed by specific enzymes like kinases, transferases, and glycosyltransferases—not the proteasome. Ubiquitination itself is a PTM that marks proteins for proteasomal degradation, but the proteasome does not perform PTM; it executes degradation of the marked protein. D. Protein sorting — This is wrong because protein sorting and trafficking to cellular compartments (ER, Golgi, mitochondria, lysosomes) is mediated by signal sequences, SNARE proteins, and vesicular transport machinery—not the proteasome. The proteasome is a fixed cytoplasmic/nuclear structure involved in degradation, not in directing proteins to their subcellular destinations.
High-Yield Facts
- 26S proteasome = 19S regulatory particle + 20S catalytic core; recognizes polyubiquitinated substrates and degrades them in an ATP-dependent manner.
- Ubiquitin-proteasome system (UPS) is the major pathway for selective intracellular protein degradation; accounts for ~80% of all protein turnover in cells.
- E3 ubiquitin ligases provide substrate specificity; >600 E3 ligases in humans determine which proteins are targeted for degradation.
- Bortezomib (proteasome inhibitor) is used in multiple myeloma treatment in India; blocks proteasomal degradation and triggers apoptosis in cancer cells.
- Proteasomal dysfunction is implicated in Parkinson's disease and Alzheimer's disease; accumulation of misfolded proteins leads to neurodegeneration.
- Proteasome inhibitors are contraindicated in pregnancy and severe renal impairment; dose adjustment required in Indian patients with hepatic dysfunction.
Mnemonics
UPS = Ubiquitin-Proteasome System Ubiquitin tags → Proteasome degrades → Selective removal. Remember: Ubiquitin is the 'death label,' proteasome is the 'executioner.' Use this when distinguishing proteasomal degradation from other protein quality control mechanisms. E1-E2-E3 Cascade E1 (Activating) → E2 (Conjugating) → E3 (Ligase = specificity). E3 is the 'gatekeeper' that decides which proteins die. Recall this when asked about ubiquitination steps or substrate specificity.
NBE Trap
NBE may pair the proteasome with chaperone-mediated protein folding to trap students who confuse quality control (chaperones rescue misfolded proteins) with degradation (proteasome eliminates irreversibly damaged proteins). The distractor "protein folding" exploits this conceptual overlap.
Clinical Pearl
In Indian cancer centers, bortezomib is a first-line agent for multiple myeloma because it selectively inhibits proteasomal degradation in plasma cells, triggering apoptosis. Understanding proteasomal function is essential for interpreting side effects (peripheral neuropathy, thrombocytopenia) and drug interactions in Indian oncology practice.
_Reference: Robbins Ch. 1 (Cell Injury & Adaptation); Harper Biochemistry Ch. 39 (Protein Synthesis & Degradation); KD Tripathi Pharmacology Ch. 62 (Cancer Chemotherapy—bortezomib section)_